Combined JAK2 and HSP90 inhibition produces synergistic anti-tumour activity across preclinical glioblastoma models

Background: Glioblastoma (GBM) remains difficult to treat because of tumour heterogeneity and the limited activity of single-target therapies. Our previous phenotypic drug screen identified JAK2/STAT3 signalling and HSP90-dependent protein homeostasis as pharmacological vulnerabilities. We investigated whether combined JAK2 and HSP90 inhibition could produce broader anti-tumour activity across GBM models. Methods: Multiple JAK2 and HSP90 inhibitors were tested alone and in combination across 2- and 3-dimensional patient-derived GBM stem cell models. Drug interactions were quantified using the zero-interaction potency (ZIP) synergy model. Mechanistic studies included RNA sequencing, flow cytometry, western blotting, immunofluorescence and FUCCI live-cell imaging. Activity was also assessed in cerebral organoid GBM co-cultures, non-malignant human neural and glial cells and orthotopic GBM xenografts. Results: Combined JAK2 and HSP90 inhibition produced synergistic interactions in 12 of the 13 GBM cell lines tested, using multiple structurally distinct inhibitor pairs. Gandotinib and NMS-E973 were selected for further mechanistic studies, where the combination reduced spheroid growth and increased caspase-3 activation and PARP cleavage. Combination treatment was associated with G2/M accumulation, altered mitotic regulation, abnormal chromosome and spindle organisation, and increased gamma-H2AX signalling. Anti-tumour combination activity was maintained in cerebral organoid co-cultures, where tumour burden was reduced as assessed by imaging, histological and luciferase-based measurements, while the drug combination had relatively limited effects on non-malignant human neural and glial cell types tested over the same concentration range. In vivo, combined Pacritinib and NMS-E973 treatment significantly reduced tumour burden in orthotopic G7 xenografts compared with vehicle or either single agent. Conclusions: JAK2/HSP90 co-inhibition produces reproducible anti-tumour activity across heterogeneous GBM models and disrupts cell-cycle and mitotic progression. These findings support further evaluation of this combination strategy in GBM.

Authors

Institutions

Publication Details

Journal
bioRxiv (Cold Spring Harbor Laboratory)
Published
2026-11-19
DOI
https://doi.org/10.64898/2026.11.18.767500
Primary Topic
Glioma Diagnosis and Treatment
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Combined JAK2 and HSP90 inhibition produces synergistic anti-tumour activity across preclinical glioblastoma models

Alexander E.P. Loftus, Vanessa Smer-Barreto, Valerie G. Brunton, Margaret C. Frame et al.
bioRxiv (Cold Spring Harbor Laboratory)
Glioma Diagnosis and Treatment
preprint

Combined JAK2 and HSP90 inhibition produces synergistic anti-tumour activity across preclinical glioblastoma models

Alexander E.P. Loftus, Vanessa Smer-Barreto, Valerie G. Brunton, Margaret C. Frame, Bhuvaneish Thangaraj Selvaraj, Morwenna Muir, Fraser Laing, Steven M. Pollard, John C. Dawson, Alison F. Munro, Neil O. Carragher, Camilla Drake, Wai Kit Chan, Roza H. Ali Masalmeh, Peter W. Nagle, John O. Mason, Roderick N. Carter, Muhammad Furqan, Gillian M. Morrison, Richard J. R. Elliott, Martin Lee, Paul Baxter
preprint en

Abstract

Background: Glioblastoma (GBM) remains difficult to treat because of tumour heterogeneity and the limited activity of single-target therapies. Our previous phenotypic drug screen identified JAK2/STAT3 signalling and HSP90-dependent protein homeostasis as pharmacological vulnerabilities. We investigated whether combined JAK2 and HSP90 inhibition could produce broader anti-tumour activity across GBM models. Methods: Multiple JAK2 and HSP90 inhibitors were tested alone and in combination across 2- and 3-dimensional patient-derived GBM stem cell models. Drug interactions were quantified using the zero-interaction potency (ZIP) synergy model. Mechanistic studies included RNA sequencing, flow cytometry, western blotting, immunofluorescence and FUCCI live-cell imaging. Activity was also assessed in cerebral organoid GBM co-cultures, non-malignant human neural and glial cells and orthotopic GBM xenografts. Results: Combined JAK2 and HSP90 inhibition produced synergistic interactions in 12 of the 13 GBM cell lines tested, using multiple structurally distinct inhibitor pairs. Gandotinib and NMS-E973 were selected for further mechanistic studies, where the combination reduced spheroid growth and increased caspase-3 activation and PARP cleavage. Combination treatment was associated with G2/M accumulation, altered mitotic regulation, abnormal chromosome and spindle organisation, and increased gamma-H2AX signalling. Anti-tumour combination activity was maintained in cerebral organoid co-cultures, where tumour burden was reduced as assessed by imaging, histological and luciferase-based measurements, while the drug combination had relatively limited effects on non-malignant human neural and glial cell types tested over the same concentration range. In vivo, combined Pacritinib and NMS-E973 treatment significantly reduced tumour burden in orthotopic G7 xenografts compared with vehicle or either single agent. Conclusions: JAK2/HSP90 co-inhibition produces reproducible anti-tumour activity across heterogeneous GBM models and disrupts cell-cycle and mitotic progression. These findings support further evaluation of this combination strategy in GBM.

bioRxiv (Cold Spring Harbor Laboratory)
University of Edinburgh (GB)
Glioma Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon